Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
STOK | US
-0.40
-3.28%
Healthcare
Biotechnology
30/06/2024
04/10/2024
11.79
11.95
12.09
11.31
Stoke Therapeutics Inc. an early-stage biopharmaceutical company develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002 which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001 which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery development and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals Inc. and changed its name to Stoke Therapeutics Inc. in May 2016. Stoke Therapeutics Inc. was incorporated in 2014 and is based in Bedford Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
46.3%1 month
61.4%3 months
61.9%6 months
69.9%-
-
2.66
0.02
0.02
-3.62
24.06
-
-112.16M
620.72M
620.72M
-
-607.37
-
-18.20
-47.85
21.25
24.78
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.83
Range1M
4.84
Range3M
4.84
Rel. volume
0.49
Price X volume
4.15M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CureVac N.V | CVAC | Biotechnology | 3.02 | 679.69M | 0.67% | n/a | 10.37% |
Avid Bioservices Inc | CDMO | Biotechnology | 10.63 | 678.14M | -1.02% | n/a | 353.77% |
ORIC Pharmaceuticals Inc | ORIC | Biotechnology | 9.61 | 677.91M | -1.84% | n/a | 0.92% |
Mereo BioPharma Group plc | MREO | Biotechnology | 4.4 | 676.95M | 2.56% | n/a | 7.83% |
ATXS | ATXS | Biotechnology | 11.87 | 669.77M | 2.06% | n/a | 1.67% |
ANNX | ANNX | Biotechnology | 6.29 | 664.56M | -2.02% | n/a | 8.36% |
OLMA | OLMA | Biotechnology | 11.6 | 664.29M | -3.73% | n/a | 0.86% |
Humacyte Inc | HUMA | Biotechnology | 5.44 | 650.86M | -4.39% | n/a | -63.37% |
Arcturus Therapeutics Ltd | ARCT | Biotechnology | 23.88 | 645.77M | -6.28% | n/a | 11.94% |
Entrada Therapeutics Inc. Common Stock | TRDA | Biotechnology | 17.07 | 635.00M | 4.79% | 5.45 | 14.99% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.62 | 0.76 | Cheaper |
Ent. to Revenue | 24.06 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.66 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 61.86 | 74.67 | Par |
Debt to Equity | 0.02 | -1.82 | Expensive |
Debt to Assets | 0.02 | 0.26 | Cheaper |
Market Cap | 620.72M | 3.73B | Emerging |